BioSight Ltd.

31 articles about BioSight Ltd.

• Biosight to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that Dr. Ruth Ben Yakar, Chief Executive Officer of Biosight, will present at the Jefferies 2020 Virtual Healthcare Conference taking place from June 2-4, 2020. The company will also be available for one-on-one meetings. Presentation Details: Date: Wednesday, June 3 Time: 10 a

• Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.

  5/18/2020

  Biosight Ltd ., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the appointment of Gary Gordon, M.D., Ph.D., the former Vice President of Oncology Development at AbbVie, to its Board of Directors. “We are thrilled to have Dr. Gordon join the Board at such an exciting time in the advancement of our lead product BST-236,” said Dr. Ruth Ben Yakar, Chief E

• Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology ProgramsProceeds support clinical advancement of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity

  3/11/2020

  Biosight Ltd . today announced the raising of a $19M Series C financing. The investment is led by Israel Biotech Fund (IBF) with participation by SBI JI Innovation Fund, Arkin Bio Ventures, and additional new and existing investors.

• Biosight Announces Data to be Presented at ASH 2019 Annual Meeting

  11/19/2019

  Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, announced that results from an ongoing Phase 2b clinical trial of BST-236 (aspacytarabine) for treatment of acute myeloid leukemia (AML

• Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia

  6/4/2019

  Biosight Ltd. announced that the United States Food & Drug Administration has granted Orphan Drug Designation to BST-236, an investigational novel antimetabolite, for the treatment of acute myeloid leukemia.

• BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia

  7/11/2018

  The trial, which will be launched in the upcoming month, will be conducted in 25 medical centers in the US and Israel.

• BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia

  12/14/2017

  The results, presented at the 59th Annual ASH Meeting and Exposition by Dr. Tsila Zuckerman of the Rambam Healthcare Center, demonstrated safety and efficacy of BST-236 as a single agent in treatment of newly-diagnosed acute leukemia patients, unfit for standard induction therapy.

• BioSight Completed Patient Enrollment And Treatment In Its Extended Acute Leukemia Phase I/II Clinical Trial With BST-236, A Novel Cytarabine Pro-Drug

  8/9/2017

• BioSight Release: Arkin Holdings And Primera Capital Lead An Investment Of $13M In Biosight For An Innovative Treatment Of Acute Leukemia

  5/16/2016

• BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial

  4/20/2016

• BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial

  4/19/2016